MedTrace Logo

Spanish Registry of Systemic Treatments in Psoriasis

NCT02075697 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 3500

Last updated 2022-03-31

No results posted yet for this study

Summary

The purpose of Biobadaderm is a to study the safety of systemic therapy in psoriasis.

Conditions

Sponsors & Collaborators

  • Spanish Agency of Medicines and Health Products

    collaborator OTHER_GOV

  • Janssen, LP

    collaborator INDUSTRY

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • Pfizer

    collaborator INDUSTRY

  • AbbVie

    collaborator INDUSTRY

  • Eli Lilly and Company

    collaborator INDUSTRY

  • Novartis

    collaborator INDUSTRY

  • Boehringer Ingelheim

    collaborator INDUSTRY

  • Bristol-Myers Squibb

    collaborator INDUSTRY

  • UCB Pharma

    collaborator INDUSTRY

  • Almirall, SAS

    collaborator INDUSTRY

  • Amgen

    collaborator INDUSTRY

  • LEO Pharma

    collaborator INDUSTRY

  • Fundación Academia Española de Dermatología

    lead OTHER

Principal Investigators

  • Esteban Daudén, PhD · Hospital de La Princesa- Madrid

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2025-10-31
Completion
2025-10-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02075697 on ClinicalTrials.gov